IN2014DN09068A - - Google Patents
Info
- Publication number
- IN2014DN09068A IN2014DN09068A IN9068DEN2014A IN2014DN09068A IN 2014DN09068 A IN2014DN09068 A IN 2014DN09068A IN 9068DEN2014 A IN9068DEN2014 A IN 9068DEN2014A IN 2014DN09068 A IN2014DN09068 A IN 2014DN09068A
- Authority
- IN
- India
- Prior art keywords
- methyl
- dmydropyridin
- morpholinomethyl
- pyran
- tetrahydro
- Prior art date
Links
- 239000004305 biphenyl Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 | |
| PCT/US2013/036193 WO2013155317A1 (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09068A true IN2014DN09068A (esLanguage) | 2015-05-22 |
Family
ID=49328166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9068DEN2014 IN2014DN09068A (esLanguage) | 2012-04-13 | 2013-04-11 |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9394283B2 (esLanguage) |
| EP (4) | EP3628670B1 (esLanguage) |
| JP (3) | JP6255382B2 (esLanguage) |
| KR (4) | KR20250005505A (esLanguage) |
| CN (2) | CN104603130B (esLanguage) |
| AU (2) | AU2013245878B2 (esLanguage) |
| BR (1) | BR112014025508B1 (esLanguage) |
| CA (1) | CA2870005C (esLanguage) |
| CY (2) | CY1119383T1 (esLanguage) |
| DK (3) | DK3628670T3 (esLanguage) |
| ES (3) | ES2745016T3 (esLanguage) |
| HR (2) | HRP20170295T1 (esLanguage) |
| HU (3) | HUE045353T2 (esLanguage) |
| IL (4) | IL296199B2 (esLanguage) |
| IN (1) | IN2014DN09068A (esLanguage) |
| LT (2) | LT2836491T (esLanguage) |
| MX (2) | MX362339B (esLanguage) |
| NZ (1) | NZ700761A (esLanguage) |
| PL (3) | PL2836491T3 (esLanguage) |
| PT (3) | PT3184523T (esLanguage) |
| RS (2) | RS55690B1 (esLanguage) |
| RU (1) | RU2658911C2 (esLanguage) |
| SG (3) | SG10201608577RA (esLanguage) |
| SI (2) | SI3184523T1 (esLanguage) |
| SM (2) | SMT201700132T1 (esLanguage) |
| WO (1) | WO2013155317A1 (esLanguage) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AU2013216721B2 (en) | 2012-02-10 | 2017-09-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| RU2699546C2 (ru) | 2012-04-13 | 2019-09-06 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| DK3628670T3 (da) | 2012-04-13 | 2022-12-05 | Epizyme Inc | Saltform til ezh2-hæmning |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| KR102057366B1 (ko) | 2012-10-15 | 2019-12-18 | 에피자임, 인코포레이티드 | 치환된 벤젠 화합물 |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SG11201508203TA (en) | 2013-04-30 | 2015-11-27 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
| AU2014288839B2 (en) | 2013-07-10 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| ES2960953T3 (es) | 2013-10-16 | 2024-03-07 | Epizyme Inc | Forma de sal de clorhidrato para la inhibición de EZH2 |
| EP3057594A4 (en) * | 2013-10-18 | 2017-06-07 | Epizyme, Inc. | Method of treating cancer |
| WO2015077193A1 (en) * | 2013-11-19 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| MX373187B (es) | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| MX383866B (es) | 2014-06-17 | 2025-03-14 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
| CA2952830C (en) | 2014-06-20 | 2022-11-01 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| FI3220916T3 (fi) * | 2014-11-17 | 2023-06-19 | Epizyme Inc | Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2016172199A1 (en) | 2015-04-20 | 2016-10-27 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2016201328A1 (en) | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| IL307260A (en) | 2015-08-24 | 2023-11-01 | Epizyme Inc | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| JP2019503391A (ja) | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| EP3464643A4 (en) | 2016-06-01 | 2020-04-01 | Epizyme Inc | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| CN109843870A (zh) | 2016-10-19 | 2019-06-04 | 星座制药公司 | Ezh2抑制剂的合成 |
| WO2018137639A1 (zh) * | 2017-01-25 | 2018-08-02 | 恩瑞生物医药科技（上海）有限公司 | 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途 |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS TO TREAT CANCER |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| WO2021127539A1 (en) * | 2019-12-20 | 2021-06-24 | Epizyme, Inc. | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
| WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| NZ277556A (en) | 1993-12-27 | 1997-06-24 | Eisai Co Ltd | N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| WO2000018725A1 (en) | 1998-09-30 | 2000-04-06 | The Procter & Gamble Company | 2-substituted ketoamides |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| ATE438624T1 (de) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| EP1477186B1 (en) | 2002-02-19 | 2009-11-11 | Shionogi & Co., Ltd. | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| US7470701B2 (en) | 2004-03-30 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Substituted 2,5-heterocyclic derivatives |
| DE602005017781D1 (de) | 2004-06-01 | 2009-12-31 | Univ North Carolina | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2006130720A2 (en) | 2005-06-02 | 2006-12-07 | University Of North Carolina At Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| CA2625189A1 (en) | 2005-10-19 | 2007-04-26 | Gruenenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
| US7973059B2 (en) | 2005-10-21 | 2011-07-05 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| CA2622615A1 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| CN101341124A (zh) | 2005-12-14 | 2009-01-07 | 布里斯托尔-迈尔斯斯奎布公司 | 可用作丝氨酸蛋白酶抑制剂的6元杂环 |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| EP2018166A2 (en) | 2006-05-15 | 2009-01-28 | Irm Llc | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors |
| CA2652634A1 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | Certain substituted quinolones, compositions, and uses thereof |
| WO2008108825A2 (en) | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
| EA019974B1 (ru) | 2007-12-19 | 2014-07-30 | Кансер Рисерч Текнолоджи Лимитед | 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2010017355A2 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| CA2784899A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| SG185431A1 (en) | 2010-05-07 | 2012-12-28 | Glaxosmithkline Llc | Indoles |
| US8637509B2 (en) * | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| KR102511807B1 (ko) | 2010-09-10 | 2023-03-20 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR102267502B1 (ko) | 2012-03-12 | 2021-06-24 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| DK3628670T3 (da) | 2012-04-13 | 2022-12-05 | Epizyme Inc | Saltform til ezh2-hæmning |
| RU2699546C2 (ru) | 2012-04-13 | 2019-09-06 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| ES2960953T3 (es) | 2013-10-16 | 2024-03-07 | Epizyme Inc | Forma de sal de clorhidrato para la inhibición de EZH2 |
-
2013
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/da active
- 2013-04-11 PT PT16191716T patent/PT3184523T/pt unknown
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/pt active IP Right Grant
- 2013-04-11 PT PT137749792T patent/PT2836491T/pt unknown
- 2013-04-11 PL PL13774979T patent/PL2836491T3/pl unknown
- 2013-04-11 SM SM20170132T patent/SMT201700132T1/it unknown
- 2013-04-11 ES ES16191716T patent/ES2745016T3/es active Active
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/zh active Active
- 2013-04-11 HR HRP20170295TT patent/HRP20170295T1/hr unknown
- 2013-04-11 RS RS20170198A patent/RS55690B1/sr unknown
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 SI SI201331566T patent/SI3184523T1/sl unknown
- 2013-04-11 PT PT191804798T patent/PT3628670T/pt unknown
- 2013-04-11 RS RSP20191175 patent/RS59392B1/sr unknown
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/pl unknown
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/lt unknown
- 2013-04-11 SM SM20190501T patent/SMT201900501T1/it unknown
- 2013-04-11 KR KR1020247041285A patent/KR20250005505A/ko active Pending
- 2013-04-11 IL IL296199A patent/IL296199B2/en unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/ko active Active
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 PL PL16191716T patent/PL3184523T3/pl unknown
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/hu unknown
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/zh active Active
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 ES ES19180479T patent/ES2931316T3/es active Active
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/ru not_active Application Discontinuation
- 2013-04-11 MX MX2014012380A patent/MX362339B/es active IP Right Grant
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/sl unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/es active Active
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/ko active Active
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/ja active Active
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/lt unknown
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en not_active Ceased
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/da active
- 2013-04-11 MX MX2019000449A patent/MX384641B/es unknown
- 2013-04-11 KR KR1020227029511A patent/KR102744039B1/ko active Active
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/hu unknown
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/el unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/ja active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/ja active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/hr unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/el unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US12251386B2/en active Active
-
2025
- 2025-02-13 US US19/053,007 patent/US20250268905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09068A (esLanguage) | ||
| SG10201901977XA (en) | Hydrochloride salt form for ezh2 inhibition | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| CO7400871A2 (es) | Compuestos de piridilo sustituidos con heteroarilo útiles como moduladores de cinasa | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| NZ709986A (en) | Pharmaceutical compositions comprising nitroxyl donors | |
| UA114325C2 (uk) | Феноксіетилпіперидинові сполуки | |
| MX2016007861A (es) | Compuestos de ácido dimetilbenzoico. | |
| MX2015017156A (es) | Inhibidores de bace. | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| TN2013000354A1 (en) | Synthesis of 2-carboxamide cycloamino urea derivatives | |
| MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
| MX345264B (es) | Derivado de azol. | |
| IN2013MU03565A (esLanguage) | ||
| PE20142433A1 (es) | Proceso para la elaboracion de undecapeptidos ciclicos | |
| PH12013502212B1 (en) | 5-membered ring heteroaromatic derivatives having npy y5 receptor antagonistic activity | |
| UA79385U (ru) | Способ получения производных (((2-r-1,3-тиазол- 4-ил)метил)сульфанил)-азолов | |
| UA69858U (en) | 2-[5-(4-dimethylaminobenzylidene)-2,4-dioxothiazolidine-3-yl]-n-[5-(4-methoxyphenyl)-1,3,4-oxadiazole -2-yl]acetamide exhibiting anticancer activity | |
| UA86566U (en) | N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof |